top of page
The PURE-01 study publications track
My group pioneered the use of neoadjuvant immunotherapy in early-stage, muscle invasive disease, through the PURE-01 trial. The study tested 3 cycles of neoadjuvant pembrolizumab prior to radical cystectomy. This study inspired several clinical trials that are currently being offered to patients diagnosed with muscle-invasive bladder cancer
2018
2020
2020
2020
2020
2020
2020
2020
2020
2020
Bandini M, Ross JS, Raggi D, et al. Predicting the pathologic complete response after neoadjuvant pembrolizumab in muscle-invasive bladder cancer. J Natl Cancer Inst. 2020 Jun 9;djaa076.doi: 10.1093/jnci/djaa076. Online ahead of print
2020
bottom of page